272 related articles for article (PubMed ID: 36202136)
1. Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.
Wu L; Yin L; Ma L; Yang J; Yang F; Sun B; Nianzeng X
Aging (Albany NY); 2022 Oct; 14(19):7890-7905. PubMed ID: 36202136
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-20a-5p suppresses tumor angiogenesis of non-small cell lung cancer through RRM2-mediated PI3K/Akt signaling pathway.
Han J; Hu J; Sun F; Bian H; Tang B; Fang X
Mol Cell Biochem; 2021 Feb; 476(2):689-698. PubMed ID: 33125611
[TBL] [Abstract][Full Text] [Related]
3. LncRNA HOTAIR facilitates proliferation and represses apoptosis of retinoblastoma cells through the miR-20b-5p/RRM2/PI3K/AKT axis.
Fu K; Zhang K; Zhang X
Orphanet J Rare Dis; 2022 Mar; 17(1):119. PubMed ID: 35248107
[TBL] [Abstract][Full Text] [Related]
4. DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2.
Liang WH; Li N; Yuan ZQ; Qian XL; Wang ZH
Mol Carcinog; 2019 Apr; 58(4):461-473. PubMed ID: 30457164
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA LINC00958 regulates cell sensitivity to radiotherapy through RRM2 by binding to microRNA-5095 in cervical cancer.
Zhao H; Zheng GH; Li GC; Xin L; Wang YS; Chen Y; Zheng XM
J Cell Physiol; 2019 Dec; 234(12):23349-23359. PubMed ID: 31169309
[TBL] [Abstract][Full Text] [Related]
6. The SNHG16/miR-30a axis promotes breast cancer cell proliferation and invasion by regulating RRM2.
Du SM
Neoplasma; 2020 May; 67(3):567-575. PubMed ID: 32122142
[TBL] [Abstract][Full Text] [Related]
7. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
8. Ribonucleotide reductase M2 subunit silencing suppresses tumorigenesis in pancreatic cancer via inactivation of PI3K/AKT/mTOR pathway.
Shan J; Wang Z; Mo Q; Long J; Fan Y; Cheng L; Zhang T; Liu X; Wang X
Pancreatology; 2022 Apr; 22(3):401-413. PubMed ID: 35300916
[TBL] [Abstract][Full Text] [Related]
9. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
Mazzu YZ; Armenia J; Chakraborty G; Yoshikawa Y; Coggins SA; Nandakumar S; Gerke TA; Pomerantz MM; Qiu X; Zhao H; Atiq M; Khan N; Komura K; Lee GM; Fine SW; Bell C; O'Connor E; Long HW; Freedman ML; Kim B; Kantoff PW
Clin Cancer Res; 2019 Jul; 25(14):4480-4492. PubMed ID: 30996073
[TBL] [Abstract][Full Text] [Related]
10. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.
Chow Z; Johnson J; Chauhan A; Jeong JC; Castle JT; Izumi T; Weiss H; Townsend CM; Schrader J; Anthony L; Yang ES; Evers BM; Rychahou P
Cancer Lett; 2024 Aug; 596():216993. PubMed ID: 38801884
[TBL] [Abstract][Full Text] [Related]
12. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R
PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963
[TBL] [Abstract][Full Text] [Related]
13. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
Fang Z; Gong C; Liu H; Zhang X; Mei L; Song M; Qiu L; Luo S; Zhu Z; Zhang R; Gu H; Chen X
Biochem Biophys Res Commun; 2015 Aug; 464(2):407-15. PubMed ID: 26093293
[TBL] [Abstract][Full Text] [Related]
14. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
PeerJ; 2022; 10():e14432. PubMed ID: 36518297
[TBL] [Abstract][Full Text] [Related]
15. LncRNA PART1 Stimulates the Development of Ovarian Cancer by Up-regulating RACGAP1 and RRM2.
Li H; Lei Y; Li S; Li F; Lei J
Reprod Sci; 2022 Aug; 29(8):2224-2235. PubMed ID: 35553409
[TBL] [Abstract][Full Text] [Related]
16. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
[TBL] [Abstract][Full Text] [Related]
17. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
Lu H; Lu S; Yang D; Zhang L; Ye J; Li M; Hu W
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30777929
[TBL] [Abstract][Full Text] [Related]
18. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.
Zhang YW; Jones TL; Martin SE; Caplen NJ; Pommier Y
J Biol Chem; 2009 Jul; 284(27):18085-95. PubMed ID: 19416980
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
[TBL] [Abstract][Full Text] [Related]
20. Ribonucleotide reductase subunit M2 is a potential prognostic marker and therapeutic target for soft tissue sarcoma.
Das B; Jain N; Mallick B
Gene; 2022 Jan; 808():145988. PubMed ID: 34624457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
